Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Malignancy: early-phase trial registry
4 of 9 indexed Malignancy trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,916 of 28,707 conditions by registered trial count.
9 US clinical trials · 4 currently recruiting · #1,916 of 28,707 conditions by registered trial count
Malignancy: 9 US clinical trials tracked, 4 recruiting.
Malignancy is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Taher Abu Hejleh, running 1 of these trials.
Enrollment posture brief
Registry condition malignancy
OPEN 4 | RECR 44% | LATE 0 | EARLY 4 | RANK #1916 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Ischemic Stroke (44% recruiting · 27 trials)
Malignancy lists 4 open slots (44% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Malignancy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Malignancy is recruiting below its size-band peers.
4 of 9 indexed trials (44.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Malignancy trials is spread across many organizations.
Taher Abu Hejleh accounts for 1 of 9 trials (11.1%). 9 distinct sponsors appear on at least one study for this condition label.
-
Typical Malignancy enrolment sits around 75 participants.
Median target enrolment is 75 among the 9 trials that report a genuine target (sentinel values excluded). 5 of those (55.6%) plan for fewer than 100 participants.
-
Malignancy splits between interventional and observational designs.
5 interventional and 4 observational studies make up this index (55.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
9 total, page 1 of 1
BostonGene-Integrated Genomic Registry (BIGR)
BostonGene
NCT04991922
Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
Alliance for Clinical Trials in Oncology
NCT04242095
Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials
University of Chicago
NCT05886764
Evaluating Informatics-assisted Immune-related Adverse Event Detection to Improve Registration Onto a Biorepository
Brigham and Women's Hospital
NCT06789601
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
National Cancer Institute (NCI)
NCT00092222
Immuno-Oncology Database and Bioregistry
UNC Lineberger Comprehensive Cancer Center
NCT04656873
Microbiome in Lung Cancer and Other Malignancies
Taher Abu Hejleh
NCT03688347
Allogeneic Transplantation From Related Haploidentical Donors
Stanford University
NCT00185692
Feasibility Study of Intra-Tumoral Lipopolysaccharide Immunotherapy for Intra-Abdominal
Patrick Wagner, MD, FACS
NCT05751837
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Malignancy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Malignancy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Malignancy page
9 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Malignancy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Taher Abu Hejleh sponsors the most Malignancy trials on record, review their full trial history before evaluating a specific study. See Taher Abu Hejleh's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Malignancy condition card totals 9 registered trials; most-linked intervention Medical Chart Review; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.